Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.92 -0.19 (-0.23%)
Official Closing Price Updated: 4:10 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK
From Robbins LLP
Via GlobeNewswire
Looking Into Merck & Co's Recent Short Interest
 
Via Benzinga
Europe Approves Merck's Cancer Drug For Two Indications
Merck's Welireg receives conditional EU approval for VHL disease-associated tumors and advanced RCC, expanding its global presence across 30+ countries. 
Via Benzinga
This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock
 
Via Benzinga
Why NYSE:MRK is a Top Pick for Dividend Investors.
Why MERCK & CO. INC. (NYSE:MRK) provides a good dividend, while having solid fundamentals. 
Via Chartmill
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
From Merck & Co., Inc.
Via Business Wire
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Decoding Merck & Co's Options Activity: What's the Big Picture?
 
Via Benzinga
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $54K Worth of Merck & Co Stock
 
Via Benzinga
MRK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
MarketBeat Week in Review – 02/10 - 02/14
Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in 
Via MarketBeat
Topics Credit Cards Economy Government
Market Whales and Their Recent Bets on MRK Options
 
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Month
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals.
MERCK & CO. INC. has caught the attention as a great value stock. NYSE:MRK excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
MRK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump's Secretary Of Health: Health Care Stocks To Watch
The U.S. Senate voted on Thursday to confirm President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Benzinga
Topics Government
3 Blue-Chip Dividend Stocks Trading at Multiyear Lows
Via The Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Via The Motley Fool
Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK
From The Rosen Law Firm, P.A.
Via Business Wire
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes
This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments. 
Via Stocktwits
Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. 
Via The Motley Fool
Merck Stock Heads For 5th Day Of Losses As TD Cowen Downgrades On Gardasil Woes, But Retail Holds Strong
The HPV vaccine had been a key growth driver in China until last year when economic headwinds disrupted demand. 
Via Stocktwits
Merck: 4 No-Brainer Reasons to Buy This Dip
Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity. 
Via MarketBeat
Better High-Yield Dividend Stock: Pfizer vs. Merck
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.